"The US Food and Drug Administration (FDA) has approved a foam containing calcipotriene and betamethasone dipropionate (Enstilar, Leo Pharma Inc) for topical treatment of plaque psoriasis in adults 18 years of age and older, according to a "...
SORILUX (calcipotriene foam) Foam is indicated for the topical treatment of plaque psoriasis in patients aged 18 years and older.
DOSAGE AND ADMINISTRATION
For topical use only. SORILUX (calcipotriene foam) Foam is not for oral, ophthalmic, or intravaginal use.
Apply a thin layer of SORILUX (calcipotriene foam) Foam twice daily to the affected areas and rub in gently and completely.
Dosage Forms And Strengths
0.005%, white foam
SORILUX (calcipotriene) Foam, 0.005%, is supplied as follows:
60 g aluminum can NDC 0145-2130-06
Storage and Handling
- Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
- FLAMMABLE. AVOID FIRE. FLAME. OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C).
- Avoid contact with eyes.
- Keep out of reach of children.
Manufactured for: Stiefel Laboratories, Inc. Research Triangle Park, NC 27709. Manufactured by: DPT Laboratories, Ltd. 307 E. Josephine Street San Antonio, TX 78215. Revised: 2010This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/2/2010
Additional Sorilux Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.